Ferrocene-Diiron(I) Bis(cyclopentadienyl) Conjugates Exhibit Potent In Vitro Cytotoxicity and Selectivity toward...

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Materials Science

Background:

• Iron-based compounds are increasingly explored for therapeutic applications.
• Developing novel organometallic complexes with tailored properties is crucial for drug discovery.
• Understanding structure-activity relationships is key to designing effective anticancer agents.

Purpose of the Study:

• To synthesize and characterize novel triiron compounds.
• To evaluate the cytotoxic activity and selectivity of these compounds against various cancer cell lines.
• To investigate the mechanism of action and preliminary pharmacokinetic properties.

Main Methods:

• Synthesis of eleven new triiron compounds via ligand substitution and alkyne-coupling reactions.
• Characterization using IR, NMR spectroscopy, cyclic voltammetry, X-ray diffraction, and DFT calculations.
• Cytotoxicity assays (IC50 values) against five cancer cell lines and normal fibroblasts.
• Assessment of water solubility, Log P, stability in physiological solutions, intracellular reactive oxygen species (ROS) levels, and preliminary biomolecular interactions (BSA, DNA).

Main Results:

• Successful synthesis of eleven triiron compounds in good yields.
• Compounds exhibit near millimolar water solubility and stability in physiological conditions.
• Potent and selective cytotoxicity against cancer cell lines (nanomolar IC50 values) with high selectivity over fibroblasts.
• Mechanism of action linked to a decrease in intracellular ROS.
• Low binding affinity to bovine serum albumin (BSA) and moderate DNA interaction observed.

Conclusions:

• The novel triiron compounds possess promising anticancer properties, including potent cytotoxicity and selectivity.
• Their favorable solubility, stability, and mechanism of action (ROS reduction) make them attractive candidates for further investigation.
• Preliminary studies suggest a low potential for non-specific protein binding, which is advantageous for drug development.